Kevin C. Gorman, Ph.D.
President, Chief Executive Officer
Kevin C. Gorman, Ph.D is a founder and previously served as Chief Operating Officer after having served as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development of Neurocrine Biosciences. From 1990 until joining Neurocrine in 1993, Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of Neurocrine and several other biotechnology companies such as Onyx Pharmaceuticals, Metra Biosystems, IDUN and ARIAD Pharmaceuticals. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.
Tim Coughlin, C.P.A.
Chief Financial Officer
Tim Coughlin was appointed Chief Financial Officer in September 2006 after having served as Vice President, Controller of Neurocrine Biosciences since 2002. He is responsible for Accounting/Finance, Information Technology, and Investor Relations. Prior to joining Neurocrine, Tim had experience in corporate accounting, finance and operations management of companies ranging in size from start-ups through Fortune 500. Prior to Neurocrine, he was with CHI, a nationwide integrated healthcare delivery system where he served as Vice President, Financial Services. Tim also served as a Senior Manager with Ernst & Young and its predecessors in their Health Science practice from 1989 - 1999. He currently serves as a member of the Board of Directors for Fate Therapeutics, a publicly traded company focused on stem cell research. Mr. Coughlin holds a Bachelors in Accounting from Temple University and Masters in International Business from San Diego State University and is also a certified public accountant in both California and Pennsylvania.
Dr. Christopher O’Brien
Chief Medical Officer
Dr. O'Brien, is responsible for all clinical development and medical affairs activities. A leader in neurological clinical research and development for over 20 years, Dr. O'Brien has participated in more than 100 clinical trials and authored more than 75 publications in the neuroscience literature. From 2000 to 2005, Dr. O'Brien held positions at Elan Pharmaceuticals and Prestwick Pharmaceuticals where he managed the clinical development, registration and post-marketing trials in neurology, pain, and autoimmune diseases, among other CNS indications. Prior to joining Elan, Dr. O'Brien also served as Medical Director for over nine years with The Colorado Neurology Institute in Denver and simultaneously served as Associate Professor at the University of Colorado, Chair of the Department of Medicine at the Columbia Swedish Medical Center and Medical Director of the National Parkinson's Foundation Center of Excellence. Dr. O'Brien earned his B.A. from Boston University and M.D. from the University of Minnesota.
Haig Bozigian, Ph.D
Chief Development Officer
Dr. Bozigian is responsible for all preclinical, chemical and pharmaceutical development at Neurocrine Biosciences. Dr. Bozigian joined Neurocrine in 1997. He has held several positions at Neurocrine, most recently as its Vice President of Preclinical Development. Dr. Bozigian has extensive expertise in endocrine and CNS related new product development. Prior to joining Neurocrine, Dr. Bozigian served as Director of Pharmaceutical Development at Procyte Corporation, Associate Director of Pharmacokinetics and Drug Metabolism at Sphinx Pharmaceuticals and Clinical Pharmacokineticist at GlaxoSmithKline. Dr. Bozigian earned his B.S. in microbiology from the University of Massachusetts, his M.S. in pharmacodynamics and toxicology from the University of Nebraska Medical Center, and earned his Ph.D. in pharmaceutical sciences from the University of Arizona.
Dimitri E. Grigoriadis. Ph.D.
Chief Research Officer
Dr. Grigoriadis, is responsible for all research activities at Neurocrine. Dr. Grigoriadis is a recognized leader in CRF receptor antagonist development, has authored or co-authored over 200 publications in the neuroscience and neuropharmacology fields, and is a current Fellow of the American College of Neuropsychopharmacology (ACNP). Dr. Grigoriadis joined Neurocrine in 1993 and was most recently Vice President of Discovery Biology. He was previously with the Neuroscience group at The Du Pont Pharmaceutical Company from 1990 to 1993. Dr. Grigoriadis received his B. Sc. from the University of Guelph in Ontario Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on Drug Abuse in Baltimore from 1987 to 1990.
Kyle Gano, Ph.D
Chief Business Development Officer
Dr. Gano is responsible for all Business and Corporate Development activities at Neurocrine including the management of ongoing collaborations with AbbVie, Mitsubishi Tanabe Pharma, and Sumitomo Dainippon Pharma. From 2001 to 2011 he held several positions of increasing responsibility at Neurocrine spanning Marketing Analytics to Business Development. Dr. Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and M.B.A. in Finance from the University of California, Los Angeles.
Chief Regulatory Officer
Malcolm Lloyd-Smith was appointed Chief Regulatory Officer in September 2014 and is responsible for Regulatory Affairs and Quality Assurance. Prior to joining Neurocrine, Mr. Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014, and previously as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008, after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA and UK. Mr. Lloyd-Smith holds a B.Sc. in pharmacology from the University of Leeds, and a M.Sc. in pharmacological biochemistry from Hatfield Polytechnic.
Chief Legal Officer
Darin Lippoldt was appointed Chief Legal Officer in October 2014. He is responsible for all Corporate Legal matters and serves as Corporate Secretary. Prior to joining Neurocrine, Mr. Lippoldt served as Executive Vice President and General Counsel of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations, and a J.D. from St Mary's University.
Chief Commercial Officer
Mr. Benevich was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing and sales of the Neurocrine product portfolio. Mr. Benevich was most recently at Avanir Pharmaceuticals as Vice President of Marketing where he was responsible for NUEDEXTA® and commercialization of their CNS pipeline. Mr. Benevich has over 20 years of experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at Peninsula Pharmaceuticals, Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel®, Epogen® and Prilosec®. Mr. Benevich has a BBA in international business from Washington State University.